

ARIZONA STATE BOARD OF HOMEOPATHIC and INTEGRATED MEDICINE EXAMINERS

AGENDA

REGULAR MEETING

Tuesday, September 8, 2015 9:00 a.m.

1400 W. Washington

Basement Conference Room, B-1

Phoenix, Arizona 85007

A public meeting of the Arizona Board of Homeopathic and Integrated Medicine Examiners will be called to order at 9:00 a.m. The Board may enter into Executive Session at any time to obtain legal advice (A.R.S. §38-431.03(A)(3)) or consider confidential material (ARS §38-431.03(A)(2)). Please be aware that the Board may take action on any item listed on the agenda. Except for those items indicating a specific time, the presiding officer will set the order of the agenda.

Persons needing reasonable accommodation, such as this document in an alternative format or a sign language interpreter, may contact Christine Springer, at her direct line:602-542-8154 or (TTY 1-800-352-8400). Please make your request as early as possible to allow time to arrange the accommodation.

I. Call to Order, Roll Call

II. Review, Consideration, and Action on Minutes

Regular Meeting Minutes – May 12, 2015

Examination Committee – Executive Session June 17, 2015

Examination Committee - Regular Session June 17, 2015

III. Status of Board Member Appointments and Annual Meeting

1. Election of Officers - A.R.S. § 32-2903(A)

2. 2015-2016 Meeting Schedule - A.R.S. § 32-2903(B)

3. Fees - A.R.S. § 32-2914

IV. Review, Consideration and Action on New Applications

Physicians

No applications

Medical Assistants

Beata George

Shelley Ann Mata

V. Rules, Legislation, Substantive Policy Statements

Legislation

Discussion - potential legislation 2016

VI. Review, Consideration, and Action on Complaints and Investigations

On any one of the matters listed under Subsection A. or B. below, the Board may go into Executive Session to consider records exempt from public inspection pursuant to ARS §38-431.03(A)(2) or to obtain legal advice pursuant to ARS§ 38-431.03(A)(3).

A. Review, Discuss, Action – Tracking Log Notification of New Complaints Filed

The following listed matters are pending and may be discussed at the meeting. They may vote to take any of the following actions: determine if a complaint should be opened and an investigation

conducted, table the matter, or determine jurisdiction pursuant to the provisions of A.R.S. §32-2907. The Board may also vote to take action to protect the public pursuant to the provisions of A.R.S. §32-2934(D) regarding summary suspension. The Board may also vote to dismiss the complaint, file a letter of concern, or issue a nondisciplinary order requiring continuing education pursuant to ARS §32-2934(E).

Inquiry No. 15-06

Thomas Lodi MD(H) – use of abbreviation

Inquiry No. 15-04

Pieter De Wet, MD(H) – Texas Medical Board Action

B. Ongoing Investigations – Review, Consideration and Action

The Board may enter into Executive Session at any time on any of the following cases to obtain legal advice (A.R.S. §38-431.03(A)(3)), or consider confidential material (ARS §38-431.03(A)(2)).

Inquiry No. 14-03

Martha Grout, MD, MD(H) – Patient M.B.

The Board may review the medical investigator report and consider (pursuant to A.R.S. §32-2934) whether to conduct further investigation, issue a letter of concern, dismiss the matter, require continuing education, or conduct an informal interview.

VII. Review, Consideration and Action on Previous Board Orders

The Board may enter into Executive Session at any time on one or more of the cases listed to obtain legal advice pursuant to A.R.S. § 38-431.03(A)(3)), or to consider confidential materials (A.R.S. §38-431.03(A)(2)).

Charles Crosby, MD(H)

Quarterly Report

Case 05-21

VIII. Review, Consideration, and Action on Professional Business

The Board may discuss these matters in executive session pursuant to ARS §38-431-03(A)(2) and §38-431-03(A)(3)

1. Status report from Examination Committee. The Board may adjourn to executive session to consider confidential material related to the examination pursuant to A.R.S. §32-431.03(A)(2).
 - a) Review, consideration, and vote on number of homeopathic remedies relative to written examination
 - b) Review, consideration, and vote concerning the number of questions, structure and format of the written examination
2. Status update regarding A.R.S. § 36-2606 and the collection and reporting of information to the State Board of Pharmacy for the purpose of Controlled Substances Prescription Monitoring Program (CSPMP) registration. Review forms applicants will use to report information to Pharmacy Board
3. Discussion and update regarding Board Member training in conformance with A.R.S. § 32-3218

IX. Review, Consideration, and Action Informed Consents/Protocols – (AAC R4-38-111)

1. Review Informed Consents submitted by Dr. Lester Adler, MD, MD(H)

- a. Consent for NAD (Nicotinamide Adenine Dinucleotide) Plus Administration
- b. Consent for Ozone Administration

2. Review Informed Consents submitted by Dr. Dean Silver, MD, MD(H)

The following consents were reviewed by Dr. Adler:

- a. Consent to Homeopathic and Integrative Medical Care
- b. Consent to Receive Insulin and Antibiotic Delivery with or without Curcumin, Quercetin, Resveratrol, Homeopathic Injection Therapy
- c. Consent to Receive Insulin Potentiated Therapy (IPT) Chemotherapy
- d. Consent for Insulin Potentiation Therapy
- e. Consent to receive Insulin Potentiated Therapy (IPT)
- f. Consent to receive Insulin Potentiated Curcumin

- g. Consent to Receive Insulin Potentiated Therapy (IPT) with or without Curcumin, Quercetin, Resveratrol, Biological Injection Therapy

The following consents were reviewed by Dr. Shelton:

- a. Consent to Receive Intramuscular and Intravenous Complex Homeopathy Therapeutics
- b. Heavy Metal Detoxification – Chelation
- c. Consent to Receive Intravenous Custom Compounded Treatment of Complex Curcumin
- d. Consent to Receive Intravenous Custom Compounded DMPS Chelation
- e. Consent to Receive Custom Compounded EDTA Chelation
- f. Consent to Receive Intravenous Fluconazole
- g. Consent to Receive Intravenous Glutathione

The following consents were reviewed by Dr. Warner:

- a. Consent to Receive Intravenous Custom Compounded HCL
- b. Consent to Receive Intravenous Hydrogen Peroxide and or DMSO
- c. Consent to Receive Intravenous Custom Compounded Immunity Support
- d. Consent to Receive Intravenous Mannitol
- e. Consent to Receive Intravenous Custom Compounded Mitochondria Therapy
- f. Consent to Receive Intravenous Minerals Therapy
- g. Consent to Receive Intravenous Nebulizer Therapy

The following consents were reviewed by Dr. Schwengel:

- a. Consent to Receive Intravenous Custom Compounded Phosphatidylcholine
- b. Consent to Receive Intravenous Custom Compounded Melatonin
- c. Consent to Receive Intravenous Custom Compounded POLY MVA
- d. Consent to Receive Intravenous Custom Compounded Treatment of Complex Quercetin
- e. Consent to Receive Genetically Targeted Chemotherapy (GTC) with Insulin Potentiated Therapy
- f. Consent to Receive Intravenous Custom Compounded Treatment of Resveratrol (Pterostilbene)
- g. Consent to Receive Intravenous Oxygenated Saline/Blood-Oxygenation Therapy Ozone/Ozonated Saline, Ultra-Violet Blood Irradiation (UVB)
- h. Consent for Prolozone Procedure

X. Review, Consideration and Action On Other Business

- 1. Financial Report and status of Office Workload - Executive Director
- 2. FY2017 Budget Submission and AZIPS Report

XI. Call to the Public

Pursuant to A.R.S. § 38-431.01(H) Board members are not allowed to discuss or take legal action on matters raised during an open call to the public unless the matters are properly noticed for discussion and legal action. Members may ask staff to review a matter or may ask that a matter be placed on a future agenda.

XII. Future Agenda Items

XIII. Future Meeting Dates

XIV. Adjournment